Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).

Details

Ressource 1Download: Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer.pdf (825.09 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_DB15DFAD9CDF
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).
Journal
European journal of cancer
Author(s)
Mathevet P., Lécuru F., Uzan C., Boutitie F., Magaud L., Guyon F., Querleu D., Fourchotte V., Baron M., Bats A.S.
Working group(s)
Senticol 2 group
Contributor(s)
Morice P., Mathevet P., Stoeckle E., Querleu D., Fourchotte V., Lécuru F., Bats A.S., Baron M., Graesslin O., Lévèque J., Ott B., Daraï E., Lanvin D., Pomel C., Marret H., Mage G., Houvenaeghel G., Baldauf J.J., Conri V., Douvier S., Delpech Y., Leblanc E., Fouché Y., Boulanger L., Descamps P., Classe J.M., Raudrant D., Rouanet P.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Publication state
Published
Issued date
05/2021
Peer-reviewed
Oui
Volume
148
Pages
307-315
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Pelvic lymph node dissection has been the standard of care for patients with early cervical cancer. Sentinel node (SN) mapping is safe and feasible and may increase the detection of metastatic disease, but benefits of omitting pelvic lymph node dissection in terms of decreased morbidity have not been demonstrated.
In an open-label study, patients with early cervical carcinoma (FIGO 2009 stage IA2 to IIA1) were randomly assigned to SN resection alone (SN arm) or SN and pelvic lymph node dissection (SN + PLND arm). SN resection was followed by radical surgery of the tumour (radical hysterectomy or radical trachelectomy). The primary end-point was morbidity related to the lymph node dissection; 3-year recurrence-free survival was a secondary end-point.
A total of 206 patients were eligible and randomly assigned to the SN arm (105 patients) or SN + PLND arm (101 patients). Most patients had stage IB1 lesion (87.4%). No false-negative case was observed in SN + PLND arm. Lymphatic morbidity was significantly lower in the SN arm (31.4%) than in the SN + PLND arm (51.5%; p = 0.0046), as was the rate of postoperative neurological symptoms (7.8% vs. 20.6%, p = 0.01, respectively). However, there was no significant difference in the proportion of patients with significant lymphoedema between the two groups. During the 6-month postoperative period, the difference in morbidity decreased over time. The 3-year recurrence-free survival was not significantly different (92.0% in SN arm and 94.4% in SN + PLND arm).
SN resection alone is associated with early decreased lymphatic morbidity when compared with SN + PLND in early cervical cancer.
Keywords
Adenocarcinoma/pathology, Adenocarcinoma/surgery, Adult, Carcinoma, Squamous Cell/pathology, Carcinoma, Squamous Cell/surgery, Female, Follow-Up Studies, Humans, Hysterectomy/mortality, Lymph Node Excision/mortality, Middle Aged, Morbidity, Neoplasm Recurrence, Local/epidemiology, Neoplasm Recurrence, Local/pathology, Prognosis, Prospective Studies, Sentinel Lymph Node Biopsy/mortality, Survival Rate, Uterine Cervical Neoplasms/pathology, Uterine Cervical Neoplasms/surgery, Lymphadenectomy, Quality of life, Sentinel node biopsy, Uterine cervical neoplasm
Pubmed
Web of science
Open Access
Yes
Create date
02/04/2021 13:58
Last modification date
09/01/2024 7:27
Usage data